Tesamorelin vs Sermorelin
Medically reviewed by the Rite Aid Health Team · Last updated August 14, 2026
Tesamorelin and sermorelin are growth-hormone-releasing hormone analogs. Tesamorelin has controlled evidence and approved labeling for excess abdominal fat in adults with HIV and lipodystrophy. Sermorelin has historical pediatric research and current compounded use, but no currently approved drug product.
Get the Free Peptide Tracking Toolkit
Tesamorelin vs Sermorelin + many more
Explore the guide, then keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
At a glance
| Comparison | Tesamorelin | Sermorelin |
|---|---|---|
| Common goal | Visceral abdominal fat in the labeled HIV-related population | Reported sleep, recovery, growth-hormone, and body-composition goals |
| Mechanism | 44-amino-acid GHRH analog with resistance to enzymatic breakdown | 29-amino-acid GHRH fragment |
| Evidence | Controlled human trials and approved labeling for one indication | Historical pediatric diagnostic and treatment research; reported current practice |
| Half-life | Minutes, with a downstream hormone response | About 10 to 20 minutes. Human pharmacokinetic study |
| Route and dosage | EGRIFTA WR 1.28 mg subcutaneously once daily; formulation-specific directions apply. EGRIFTA WR label | A physician-reviewed clinic guide reports 200 to 500 mcg subcutaneously at bedtime. Clinic practice guide |
| Side effects | Injection reactions, joint pain, swelling, tingling, glucose changes, and hypersensitivity | Injection reactions, headache, flushing, dizziness, and growth-hormone-axis effects are reported |
| Monitoring | IGF-1, glucose status, clinical response, and label-specific warnings | IGF-1, glucose, symptoms, and product quality are commonly reviewed |
| Access and status | FDA-approved prescription product for a narrow indication | Compounded prescription access; no current FDA-approved product |
When tesamorelin is commonly considered
Tesamorelin is the evidence-based choice when the person matches its approved HIV-related lipodystrophy population and visceral-fat goal. It is not labeled for general weight management, and EGRIFTA WR and EGRIFTA SV have different preparation and dosing instructions.
When sermorelin is commonly considered
Sermorelin appears in compounded practice for broader growth-hormone-axis goals. A physician-reviewed clinic guide describes a once-daily bedtime pattern, which contrasts with tesamorelin’s disease-specific label and formulation instructions. Sources: Clinic practice guide
Why combining them usually adds overlap
Both act at the GHRH receptor and aim to stimulate the same pituitary pathway. Combining them duplicates the primary signal, and controlled research has not established an added benefit.
Related
Sources
Get the Free Peptide Tracking Toolkit
Tesamorelin vs Sermorelin + many more
Explore the guide, then keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Tesamorelin has stronger evidence for its approved HIV-related lipodystrophy indication. That evidence does not transfer to general weight loss.
No. A compounded preparation can be prescribed for an individual patient, but it is not an FDA-approved finished drug product.